BRPI1008035A2 - anticorpos contendo peptídeos terapêuticos miméticos de tpo/epo - Google Patents

anticorpos contendo peptídeos terapêuticos miméticos de tpo/epo

Info

Publication number
BRPI1008035A2
BRPI1008035A2 BRPI1008035A BRPI1008035A BRPI1008035A2 BR PI1008035 A2 BRPI1008035 A2 BR PI1008035A2 BR PI1008035 A BRPI1008035 A BR PI1008035A BR PI1008035 A BRPI1008035 A BR PI1008035A BR PI1008035 A2 BRPI1008035 A2 BR PI1008035A2
Authority
BR
Brazil
Prior art keywords
antibodies containing
therapeutic peptides
epo mimetic
containing tpo
mimetic therapeutic
Prior art date
Application number
BRPI1008035A
Other languages
English (en)
Inventor
Gies David
P Springhorn Jeremy
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of BRPI1008035A2 publication Critical patent/BRPI1008035A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI1008035A 2009-02-24 2010-02-18 anticorpos contendo peptídeos terapêuticos miméticos de tpo/epo BRPI1008035A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20848709P 2009-02-24 2009-02-24
PCT/US2010/024546 WO2010099019A1 (en) 2009-02-24 2010-02-18 Antibodies containing therapeutic tpo/epo mimetic peptides

Publications (1)

Publication Number Publication Date
BRPI1008035A2 true BRPI1008035A2 (pt) 2017-03-21

Family

ID=42665848

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008035A BRPI1008035A2 (pt) 2009-02-24 2010-02-18 anticorpos contendo peptídeos terapêuticos miméticos de tpo/epo

Country Status (14)

Country Link
US (1) US9493551B2 (pt)
EP (2) EP2401302A4 (pt)
JP (2) JP2012518408A (pt)
KR (1) KR20110122846A (pt)
CN (1) CN102428105B (pt)
AU (1) AU2010218277B2 (pt)
BR (1) BRPI1008035A2 (pt)
CA (1) CA2753438A1 (pt)
IL (1) IL214714A0 (pt)
MX (1) MX2011008936A (pt)
NZ (2) NZ594638A (pt)
RU (1) RU2559526C2 (pt)
SG (1) SG173680A1 (pt)
WO (1) WO2010099019A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266724A1 (en) * 2007-09-18 2010-10-21 Novozymes A/S Method for producing an acidified milk drink
WO2012121958A2 (en) * 2011-03-08 2012-09-13 Glaxosmithkline Llc Combination
CN105658670A (zh) * 2013-08-21 2016-06-08 乌雷卡有限公司 肽-低聚尿素嵌合化合物及其使用方法
JP6691058B2 (ja) * 2014-12-09 2020-04-28 デンカ株式会社 燃焼時の耐ドリップ性に優れたポリアミド系人工毛髪用繊維
AU2016362777B2 (en) * 2015-12-04 2020-01-30 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
CN110662762A (zh) 2017-05-24 2020-01-07 诺华股份有限公司 抗体细胞因子移植蛋白和用于治疗癌症的方法
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
WO2018222901A1 (en) * 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
BR112020001367A2 (pt) * 2017-07-26 2020-08-11 Janssen Pharmaceutica N.V. métodos de proteção da integridade vascular induzida por terapia de radiação direcionada
JP2022523295A (ja) * 2019-01-25 2022-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 発疱剤および苛性ガスの毒性作用を緩和する方法
WO2020154585A1 (en) * 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists
CN117986346B (zh) * 2024-04-07 2024-07-26 中国人民解放军军事科学院军事医学研究院 一种tpo模拟肽及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
AU6131086A (en) 1985-07-05 1987-01-30 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
DE3852823T2 (de) 1987-09-11 1995-05-24 Hughes Howard Med Inst Transduktionsveränderte fibroblasten und ihre anwendung.
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
EP0400047B1 (en) 1988-02-05 1997-04-23 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
EP0556345B2 (en) 1990-10-31 2005-10-12 Cell Genesys, Inc. Retroviral vectors useful for gene therapy
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5830851A (en) 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
EA001220B1 (ru) 1995-06-07 2000-12-25 Глаксо Груп Лимитед Пептид или пептидомиметик, который связывается с рецептором тромбоэтина, фармацевтическая композиция и способ лечения
EP0889875B1 (en) 1996-03-29 2001-06-20 G.D. Searle & Co. Cyclopropyl alkanoic acid derivatives
US5835382A (en) 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
WO1997042217A1 (en) 1996-05-06 1997-11-13 The Uab Research Foundation Radiolabeled fusion toxins for cancer therapy
US7056897B2 (en) 1997-11-03 2006-06-06 The Arizona Board Of Regents Inducible expression vectors and methods of use thereof
BR0013231A (pt) * 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
US7091396B1 (en) 2000-10-17 2006-08-15 The Rockefeller University Animals, cells and methods for production of detectably-labeled antibodies
AU2002234001B2 (en) 2000-12-05 2008-05-01 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
WO2005021579A2 (en) * 2003-08-28 2005-03-10 Biorexis Pharmaceutical Corporation Epo mimetic peptides and fusion proteins
JP4767857B2 (ja) * 2003-09-30 2011-09-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ベンゾイミダゾール化合物
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7442778B2 (en) * 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
WO2007048022A2 (en) 2005-10-21 2007-04-26 Alexion Pharmaceuticals, Inc. Antibody-polypeptide fusion proteins and methods for producing and using same
US7625564B2 (en) * 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
EP2007602A4 (en) * 2006-03-31 2010-09-22 Centocor Ortho Biotech Inc HUMAN EPO MIMETICS IN HINGED CENTRAL REGION, COMPOSITIONS, METHODS AND USES IN THE PREVENTION OR TREATMENT OF GLUCOSE INTOLERANCE OR ANEMIA ASSOCIATED WITH NEPHROPATHY

Also Published As

Publication number Publication date
JP2012518408A (ja) 2012-08-16
JP2015043783A (ja) 2015-03-12
US20120070434A1 (en) 2012-03-22
MX2011008936A (es) 2011-09-21
EP2401302A4 (en) 2013-10-09
US9493551B2 (en) 2016-11-15
AU2010218277A1 (en) 2011-09-08
RU2011139129A (ru) 2013-04-10
CN102428105B (zh) 2015-09-30
NZ594638A (en) 2013-03-28
NZ603712A (en) 2014-05-30
AU2010218277B2 (en) 2014-07-17
CN102428105A (zh) 2012-04-25
WO2010099019A1 (en) 2010-09-02
SG173680A1 (en) 2011-09-29
IL214714A0 (en) 2011-11-30
CA2753438A1 (en) 2010-09-02
EP2401302A1 (en) 2012-01-04
EP2752427A1 (en) 2014-07-09
KR20110122846A (ko) 2011-11-11
RU2559526C2 (ru) 2015-08-10

Similar Documents

Publication Publication Date Title
SG173680A1 (en) Antibodies containing therapeutic tpo/epo mimetic peptides
EP2276499A4 (en) ANTIGEN OF RECOMBINANT GLIADINE DEAMIDED
EP2448972A4 (en) IMMUNOGLOBULIN FC POLYPEPTIDES
PL2949666T3 (pl) Ludzkie przeciwciała przeciwko alfa-synukleinie
BRPI1011005A2 (pt) anticorpos anti-epcam
PT2262831E (pt) Anticorpos antiproperdina
IL236236A (en) Antibodies to the fam26f polypeptide
EP2207803A4 (en) Cd9-specific human antibodies
EP2318438A4 (en) ANTI-P2X7 PEPTIDES AND EPITOPES
BRPI0915718A2 (pt) peptídeos de direção crkl
BRPI0922716A2 (pt) purificação de polipeptídeo
GB0815788D0 (en) Therapeutic antibodies
GB0920981D0 (en) Peptides
IL212078A0 (en) Antibodies to modified human igf-1/e peptides
IL240134A0 (en) new proteins
IT1395137B1 (it) Nuovi peptidi antipatogeni
EP2324059A4 (en) THERAPEUTIC ANTI-PAMP ANTIBODIES
EP2254901A4 (en) THERAPEUTIC PEPTIDES
EP2484694A4 (en) MONOCLONAL ANTIBODY AGAINST HUMAN H1G1 POLYPEPTIDE
GB0920987D0 (en) Peptides
EP2264057A4 (en) RECOMBINANT ANTIGEN
HK1165814A (en) Antibodies containing therapeutic tpo/epo mimetic peptides
GB0817978D0 (en) Peptides
HRP20190159T1 (hr) Antitijela humanog anti-alfa-sinukleina
UA18028S (uk) Кришка до пляшки

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]